Fri, Nov 28, 2014, 8:47 AM EST - U.S. Markets open in 43 mins.


% | $
Quotes you view appear here for quick access.

Seattle Genetics Inc. Message Board

  • ricardouno ricardouno Dec 11, 2012 7:31 AM Flag

    SGEN Highlights Two Genentech Phase I ADC Programs at ASH

    “Genentech’s phase I data and their advancement of these two ADCs into phase II clinical development, as well as their utilization of our technology in six other clinical-stage programs, illustrates their commitment to ADCs as an innovative, targeted approach to treat cancer,” said Eric Dobmeier, Chief Operating Officer of Seattle Genetics. “Across our ADC collaborations, there is broad potential for our industry-leading technology to address the significant need for more effective and better tolerated treatment options.”

    The two Genentech ADCs are to treat B cell lymphoma and will be paired with Rituxan in Phase II studies.

    Good luck!


36.79+0.14(+0.38%)Nov 26 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.